Swiss biotech companies: R & D expenses 2016-2023
This statistic show Swiss biotech companies' research and development expenses from 2016 to 2023. In 2023, Swiss biotech companies invested a total of around 2.4 billion Swiss francs into research and development.
Swiss biotech and pharma companies
Swiss biotech companies have increased their research and development (R&D) expenses in recent years, from 1.12 billion Swiss francs in 2015 to over 2.7 billion Swiss francs in 2022. In 2023, however, it increased to 2.4 billion francs. The amounts spent by public and private companies were around 1.27 billion and 1.15 billion francs, respectively. There are around 260 Swiss companies that use biotechnological technologies to develop products. Many are located around Lake Geneva, the Greater Basel Area, and the Greater Zurich Area.
Swiss company Novartis is one of the world’s largest biopharmaceutical companies based on prescription sales, generating over 50 billion U.S. dollars in 2022, in comparison, research and development spending totaled about nine billion U.S. dollars. Novartis was established in 1996 when the companies, Ciba-Geigy and Sandoz Laboratories, were merged. Currently, the company is headquartered in Basel and its campus includes works from a variety of artists and architects. Novartis' total revenues are dominated by its Innovative Medicines segment, reporting around 32 billion U.S. dollars in 2023.
Swiss biotech and pharma companies
Swiss biotech companies have increased their research and development (R&D) expenses in recent years, from 1.12 billion Swiss francs in 2015 to over 2.7 billion Swiss francs in 2022. In 2023, however, it increased to 2.4 billion francs. The amounts spent by public and private companies were around 1.27 billion and 1.15 billion francs, respectively. There are around 260 Swiss companies that use biotechnological technologies to develop products. Many are located around Lake Geneva, the Greater Basel Area, and the Greater Zurich Area.
Swiss company Novartis is one of the world’s largest biopharmaceutical companies based on prescription sales, generating over 50 billion U.S. dollars in 2022, in comparison, research and development spending totaled about nine billion U.S. dollars. Novartis was established in 1996 when the companies, Ciba-Geigy and Sandoz Laboratories, were merged. Currently, the company is headquartered in Basel and its campus includes works from a variety of artists and architects. Novartis' total revenues are dominated by its Innovative Medicines segment, reporting around 32 billion U.S. dollars in 2023.
